In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report).

Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a report ...

Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...

Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

Knees at Zimmer Biomet. "We are proud to offer a total revision knee construct with no deliberate addition of the most common metal allergens (Nickel, Cobalt, & Chromium). Metal sensitivity is one ...

Zimmer Biomet appoints Kristen Cardillo as SVP and Chief Communications Officer to lead global strategy and stakeholder engagement.

WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of ...

In the third quarter of 2024, Zimmer Biomet reported sales of $1.82 billion, representing an approximate 4% year-over-year growth and aligning with consensus estimates. The company's adjusted ...

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, has entered into a strategic distribution agreement with Promamec, a leading provider of medical devices in ...

Zimmer Biomet Holdings, Inc. (NYSE ... With a healthy current ratio of 1.91 and total debt of $6.2 billion, the company maintains a solid financial position. The company has the option to redeem ...

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our ...